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Background: Human milk is the optimal nutrition for infants. When breastfeeding is not possible, supplementation
of infant formula with long chain polyunsaturated fatty acids appears to promote neurodevelopmental outcome
and visual function. Plant oils, that are the only source of fat in most of infant formulas, do not contain specific fatty
acids that are present in human and cow milk and do not encounter milk fat triglyceride structure. Experimental
data suggest that a mix of dairy lipids and plant oils can potentiate endogenous synthesis of n-3 long chain
polyunsaturated fatty acids. This trial aims to determine the effect of an infant formula supplemented with a
mixture of dairy lipids and plant oils on the erythrocyte membrane omega-3 fatty acid profile in full-term infants
(primary outcome). Erythrocyte membrane long chain polyunsaturated fatty acids and fatty acids content, the
plasma lipid profile and the insulin-growth factor 1 level, the gastrointestinal tolerance, the changes throughout the
study in blood fatty acids content, in growth and body composition are evaluated as secondary outcomes.
Methods/Design: In a double-blind controlled randomized trial, 75 healthy full-term infants are randomly allocated
to receive for four months a formula supplemented with a mixture of dairy lipids and plant oils or a formula
containing only plant oils or a formula containing plant oils supplemented with arachidonic acid and
docosahexaenoic acid. Twenty-five breast-fed infants constitute the reference group. Erythrocyte membrane
omega-3 fatty acid profile, long chain polyunsaturated fatty acids and the other fatty acids content, the plasma lipid
profile and the insulin-growth factor 1 level are measured after four months of intervention. Gastrointestinal
tolerance, the changes in blood fatty acids content, in growth and body composition, assessed by means of an air
displacement plethysmography system, are also evaluated throughout the study.
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Discussion: The achievement of an appropriate long chain polyunsaturated fatty acids status represents an
important goal in neonatal nutrition. Gaining further insight in the effects of the supplementation of a formula with
dairy lipids and plant oils in healthy full-term infants could help to produce a formula whose fat content,
composition and structure is more similar to human milk.
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Keywords: Full-term infants, Formula supplementation, Dairy lipids, Erythrocyte membrane omega-3 fatty acid
profileBackground
Human milk is recognized as the gold standard for in-
fant nutrition [1-3]. Lipids are a major component of
human milk and provide 45% of total energy intake. The
main constituents are triacylglycerols, phospholipids and
their components fatty acids and sterols. Lipids contrib-
ute to several biological functions with regard to growth
and development. In particular, human milk provides es-
sential fatty acids (EFA) and long chain polyunsaturated
fatty acids (LC-PUFA) of omega-3 and omega-6 families,
such as docosahexaenoic acid (DHA, 22:6n-3) and ara-
chidonic acid (AA, 20:4n-6) [4]. These fatty acids consti-
tute the main components of brain tissue and have an
important impact on neuronal and visual functions [5].
LC-PUFA accretion in human brain is a slow gradual
process [6]. The last trimester of pregnancy represents a
critical period for LC-PUFA deposition whose accretion
in the nervous system endures after birth [7-9]. The de-
posit of AA during the last trimester of pregnancy differs
from that of DHA so that at term human brain contains
relatively more AA than DHA. However, after term,
DHA brain content increases, resulting in DHA being
the main LC-PUFA in adult brain. It has been demon-
strated that lipids represent 50 to 60% of dry adult brain
weight [10]. In addition, cerebral LC-PUFA concentra-
tion seems to be higher in the cortical gray matter and
lower in the white matter [11,12]. In baboon neonates,
DHA and AA have been found to be present at highest
concentrations in the precentral, postcentral, prefrontal
and occipital cortices, and also in basal ganglia, hippo-
campus, thalamus and cerebellum [12]. As these areas
are mainly involved in the development of sensor-motor
integration, attention and memory functions, these data
suggest the critical role of LC-PUFA in promoting these
skills.
Experimental studies confirmed that a deficient dietary
intake of DHA can lead to a reduced neuronal cell size,
a decreased visual function and a compromised learning
behavior [13,14].
DHA and AA can be directly provided from the diet
or be synthesized from endogenous conversion of the
precursors alpha-linolenic acid (ALA; 18:3ω3) and lino-
leic acid (LA; 18:2ω6) by enzymatic processes, which arepresent also in fetuses and infants. However, these en-
zymatic systems seem to be unable to satisfy LC-PUFA
requirements in infants until 16 weeks after birth
[15,16]. Accordingly, LC-PUFA during pregnancy are
mainly supplied by the placental transfer, whereas during
the first months of life the infant is dependent on LC-
PUFA supply through breast milk or formula [17].
Fatty acid status can be evaluated by measuring the
fatty acid composition of functional tissue such as brain
or retina. However, in clinical studies, substitute para-
meters can be used. It has been demonstrated that
erythrocyte membrane fatty acids are representative of
brain cell membranes composition, whereas serum lipid
levels are influenced by other transient factors, such as
contingent diet [18,19]. Therefore, DHA levels in
erythrocyte membrane phospholipids are commonly
used as an indicator of brain DHA status.
When breastfeeding is not possible, milk substitutes
represent the nutritional alternative. It has been demon-
strated that formula fed infants have lower levels of LC-
PUFA in their cerebral cortex than breastfed infants.
This relative deficit of LC-PUFA may partially explain
the lower Intelligence Quotient scores reported in for-
mula fed infants in comparison with breastfed infants
[20,21]. Makrides M. et al. [22] reported a positive cor-
relation between the erythrocyte DHA levels and the
visual-evoked potential acuity. In addition, the authors
demonstrated that full-term formula fed infants had
erythrocyte DHA levels lower than breast fed infants
[22]. Farquharson J. et al. [23] have found lower levels of
LC-PUFA in the cerebral cortex of infants fed a formula
enriched only with EFA than in breastfed infants. These
results suggest that formulas containing only ALA and
LA may not be adequate to satisfy the actual require-
ments of infants in terms of LC-PUFA. Furthermore, it
has been reported that infants fed a formula supplemen-
ted with DHA and AA have higher erythrocyte mem-
brane omega-3 concentrations at 9 months of age as
compared to infants fed an unsupplemented formula
[24]. Indeed, supplementation of infant formula with
LC-PUFA appears to be associated with a beneficial ef-
fect on short-term neurodevelopmental outcome and
visual function [25-27]. Although evidence concerning
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month of age is lacking, it cannot be excluded that the
positive effect of LC-PUFA supplementation may be-
come again evident at school age when infants are
required to perform tasks that necessitate more complex
neural functions [15].
Besides, DHA consumption appears to influence
infants’ body composition by promoting the develop-
ment of fat free mass without any detrimental effect on
growth [27]. Courville AB. et al. [28] have recently
demonstrated that infants of mothers consuming food
supplemented with DHA during the last half of preg-
nancy have lower ponderal indices and umbilical cord
blood insulin concentrations than infants of mothers
consuming the placebo.
Most of infant formulas available nowadays on the
market contain plant oils as the only source of fat [29].
Indeed, infant formulas have been enriched in EFA-rich
plant oils as cow milk fat does not contain enough EFA
to meet infant’s needs [30]. The main plant oils used are
coconut oil, corn oil, soybean oil, palm olein, palm ker-
nel oil, palm oil, high oleic safflower oil, peanut oil, and,
in Europe, low-erucic acid rapeseed oil. Vegetable oil-
based formulas can contain up to 4% residual milk fat
[31]. However, plant oils do not contain specific fatty
acids, particularly short chain fatty acids, that are
present in human and cow milk [32,33] and constitute a
pertinent energy source for infants [31]. In addition,
plant oils do not encounter milk fat triglyceride struc-
ture [30].
The supplementation of infant formulas with dairy
lipids could provide a fat composition and structure
closer to human milk, thus improving the quality of for-
mula fat composition. Dabadie et al. [34] demonstrated
that dairy lipids associated with rapeseed oil significantly
increased erythrocyte DHA levels adults. Recently, it has
been reported that rodents consuming a diet with a mix
of dairy lipids and plant oils showed levels of brain DHA
higher than rodents consuming a diet containing only
plant oils or a DHA-enriched diet containing plant oils,
with the same ALA contents [35]. These data suggest
that a mix of dairy lipids and ALA-rich plant oils could
potentiate endogenous n-3 LC-PUFA synthesis.Study aims
Primary aim
To investigate the effect of an infant formula supple-
mented with a mixture of dairy lipids and plant oils (for-
mula A) on the erythrocyte membrane omega-3 fatty
acid profile in healthy full-term infants as compared to a
formula containing only vegetable lipids (formula B) or
vegetable lipids supplemented with LC-PUFA (AA +
DHA) (formula C).Secondary aims
1) To compare erythrocyte membrane LC-PUFA
content of infants consuming formula A in
comparison to breastfed infants (reference group).
2) To compare the changes throughout the study in
blood fatty acids content exhibited by infants
consuming formula A in comparison to infants
consuming formula B and formula C and to
breastfed infants (reference group).
3) To compare the plasma lipid profile and the insulin-
growth factor 1 (IGF-1) levels exhibited by infants
consuming formula A in comparison to infants
consuming formula B and formula C and to
breastfed infants (reference group).
4) To investigate the gastrointestinal tolerance of
formula A.
5) To evaluate the growth and the body composition
changes exhibited by infants consuming formula A
in comparison to infants consuming formula B and
formula C and to breastfed infants (reference
group).
6) To compare the erythrocyte membrane fatty acid
profile exhibited by infants consuming formula A in
comparison to infants consuming formula B and
formula C and to breastfed infants (reference
group).Methods and design
The study is designed as a mono-centric, double-blind,
randomized controlled trial. The Ethical Committee of
the Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico, University of Milan, Italy, approves the study
protocol before the start of the study. Written informed
consent is obtained from both parents.Study population
All infants who are born in the Department of Neonat-
ology of the Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico, University of Milan, are screened
for participation in the study.
Inclusion criteria are: gestational age 37 to 42 weeks,
birth weight >2500 g, healthy newborns from normal
pregnancy, aged up to 3 weeks when entering the study.
Exclusion criteria are: newborns whose parents have
planned to move within 6 months after birth, newborns
with a positive family history of allergy to milk proteins,
newborns with known congenital or postnatal diseases
which could interfere with the study. With regard to the
reference group, additional inclusion criteria were the
intention of mothers to exclusively breastfeed their
infants at least for 4 months and being exclusively
breastfed at time of enrollment.
Table 2 Study schedule
V1 V2 V3 V4 V5
Written informed consent x
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Mothers are encouraged to breastfeed their newborn for
at least 4 months. Only if mothers cannot or intend not
to breastfeed their newborns, the study team asks the
parents for their consent to participate in the study and
to be randomized to one of the three formula groups.
Enrollment and randomization occur at the same time
and are performed within 21 days after delivery.
Infants whose mothers indicate that they intend to ex-
clusively breastfeed are included in the breastfeeding
group. This group serves as the non-randomized refer-
ence group.
The randomization schedule (provided by Lactalis
Recherche et Developpement, Nutrition Department,
Retiers, France) is computer-generated and stratified on
sex. Sequentially numbered tins of infant formula are
prepared according to this schedule. All formulas are
packaged in blinded containers labeled only with the
study details and the number of randomization; they are
indistinguishable in appearance and texture. Once the
newborn is enrolled, he/she is allocated to the next avail-
able study number which corresponds to the allocation
to one of the 3 study formulas. Both the investigators
and the infants’ parents are blind to the group allocation.
Interventions
At enrollment, each newborn is allocated to one of the
three formula groups. Newborns randomized to formula
A receive a formula containing a mixture of dairy lipids
and plant oils; newborns randomized to formula B re-
ceive a formula containing only plant oils; newborns
randomized to formula C receive a formula containing
plant oils supplemented with AA and DHA. Composi-
tions of the three formulas are detailed in Table 1. Study
formulas are started straightaway after randomization
and are provided for the four subsequent months. The
study formulas are formulated into powders and areTable 1 Composition of the infant formulas
Formula A Formula B Formula C
100 ml* 100 ml* 100 ml*
Energy kJ 275 275 275
kcal 66 66 66
Protein G 1.3 1.3 1.3
Carbohydrates G 8.1 8.1 8.1
Lactose G 6.8 6.8 6.8
Fat G 3.1 3.1 3.1
Linoleic acid mg 439 549 549
alpha linolenic acid mg 73 55 55
AA mg 12.4
DHA mg 6.2
* Reconstituted 13.3%.reconstituted at 13.3%. All study formulas are currently
on the market; they are manufactured and provided by
Lactalis, Craon, France in compliance with the European
directive on infant formulae.
Infants are fed on demand and are not allowed to
introduce complementary foods while receiving one of
the study formulas.
Study outcome measures
The study schedule is reported in Table 2.
Measurement of erythrocyte membrane and blood fatty
acid levels, plasma lipid profile (triglycerides, high density
lipoprotein, low density lipoprotein, total cholesterol) and
IGF-1 levels
Venous blood samples are drawn after consumption of
the allocated formula for 4 months. The blood is col-
lected on heparin. Plasma is separated by 15-min centri-
fugation (2200 g at 4°C) from erythrocytes that are
rinsed with saline solution (NaCl 0.9%). The plasma and
erythrocytes are stored at −80°C for later analysis.
Erythrocyte membrane FA levels are measured by
means of a gas–liquid chromatography (HPLC) by
ITERG, Pessac, France. Sum of omega-3 FA levels
includes ALA, EPA (eicosapentaenoic acid, 20:5n-3),
DPA (docosapentaenoic acid, 22:5n-3) and DHA levels.
Plasma lipid profile and IGF1 levels are measured by
means of standard techniques.
Measurement of blood FA levels
Whole blood samples are collected using a heel stick at
enrollment and after four months of consumption of thePersonal and family history x
Inclusion and exclusion criteria x
Randomization x
Phone calls x x
Heel stick blood sampling x x
Venipuncture x
Anthropometric parameters
(weight, length, head circumference)
x x x
Body composition x x x
Evaluation of onset and severity of
atopic dermatitis by means
of the SCORAD index
x x x
Adverse events Throughout the study
V1=enrollment ; V2= consumption of the allocated formula for one month;
V3= consumption of the allocated formula for two months; V4= consumption
of the allocated formula for three months; V5= consumption of the allocated
formula for four months.
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a gas–liquid chromatography (HPLC) by Oxigenlab,
Brescia, Italy.
Investigation of the gastrointestinal tolerance
Parents are contacted every four weeks either by clinic
visits or phone calls. Specifically, the following indicators
of gastrointestinal tolerance are collected after one and
three months of consumption of the allocated formula:
amount of formula consumed, regurgitation/reflux, colic
(intermittent attacks of abdominal pain when the baby
screams and draws up his/her legs but is well between
episodes), daily frequency of stool passage, stool
consistency and color. In addition, during the clinic vis-
its, the onset, if present, and the severity of atopic derma-
titis is evaluated by means of the SCORAD index [36].
Growth and body composition
Birth weight, length and head circumference are
recorded. Growth and body composition are then evalu-
ated at enrollment, after 2 and 4 months of consumption
of the allocated formula. The infants’ anthropometric
measurements (body weight, length, head circumfer-
ence) are obtained using standardized techniques [37].
Subject mass is measured on an electronic scale accurate
to the nearest 0.1 g. Recumbent length is measured on a
Harpenden stadiometer to the nearest 1 mm. The head
circumference is measured using a non-stretch measur-
ing tape to the nearest 1 mm. Z-scores for weight, length
and head circumference are then calculated with the
EUROGROWTH software (http://www.euro-growth.org/).
Body composition is assessed using an air displacement
plethysmography system (PEA POD Infant Body Com-
position System, COSMED- USA). A detailed descrip-
tion of the PEA POD’s physical design, operating
principles, validation and measurement procedures is
provided elsewhere [38,39]. The PEA POD assesses fat
mass and fat free mass by direct measurements of body
mass and volume and the application of classic densito-
metric principles. Infants are measured in the PEA
POD naked. Each PEA POD test takes about 3 min to
complete. Subject volume is measured in an enclosed
chamber by applying gas laws that relate pressure
changes to volumes of air in the chamber. Body density
is then computed from the measured body mass and
volume, and inserted into a standard formula for esti-
mating the percentage of total body fat mass according
to a 2- compartment model. The intra-observer coeffi-
cient of variation for the percentage of fat mass esti-
mates is 0.3%.
Sample size, power and statistical analysis
In order to detect a difference of 20% with a standard
deviation of 0.3 in the erythrocyte membrane omega-3fatty acids levels between infants receiving formula A
and infants receiving formula B or formula C, at a power
of 90% and with an alpha error of 5%, a total of 23
infants per group is necessary. Considering a drop out
rate of about 10%, a total of 75 formula fed infants, with
25 infants for each group, are included. Twenty-five ex-
clusively breastfed infants constitute the reference
group.
All statistical analyses are performed on an intention
to treat basis. In addition, alternative per protocol ana-
lyses are performed, excluding all infants who are not
fed according to the protocol study. Statistical analysis is
performed by Soladis, Lyon, France. For statistical ana-
lysis a p-value <0.05 is considered significant (two
tailed). All statistical analyses are performed using SPSS
12 (SPSS Inc., Chicago, IL, USA). Continuous variables
are expressed as mean, standard deviation, minimum,
maximum, median, quartiles.
The differences among groups in erythrocyte omega-3
FA levels, plasma lipid profile and IGF-1 levels are
assessed using an analysis of covariance with sex as cov-
ariate. Differences among and within groups in repeated
measurements of plasma FA levels, of growth para-
meters and body composition, are analyzed with an ana-
lysis of variance.
As the breastfed infants are not randomized, no statis-
tical analysis is performed to compare the breastfed
group with any of the formula feeding groups.
Adverse events and serious adverse events
Adverse events (AEs) are assessed based on clinical ob-
servation of the investigators or inquires to the parents.
All AEs are recorded in adverse event forms and are
evaluated by the investigator for causality for the rela-
tionship to the study feeding and for severity. An AE is
defined as any event, that is not consistent with the in-
formation provided in the consent form or can reason-
ably be expected to accompany the natural history and
progression of the subject’s condition throughout the
study. AEs are considered as serious (SAEs) if they are
fatal or life-threatening, require hospitalization or surgi-
cal intervention, result in persistent or significant dis-
ability/incapacity or are considered to be medically
relevant by the investigator. All other AEs are categor-
ized as non-serious.
Discussion
Human milk represents the optimal nutrition for infants
and ensures optimal growth and development. LC-
PUFA, which are provided through breast milk, play a
critical role in the development of neuronal and visual
functions. Hence, the achievement of an appropriate
neonatal LC-PUFA status represents an important goal
in neonatal nutrition, especially when breastfeeding is
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demonstrated to exhibit lower cerebral and erythrocyte
LC-PUFA levels as compared to breast fed infants when
consuming an unsupplemented formula or a formula
supplemented only with EFA [22,23]. On the contrary,
infants receiving a formula supplemented with DHA and
AA show higher erythrocyte membrane omega-3 con-
centrations than infants fed an unsupplemented formula
[24]. Recent experimental data indicate that a dairy fat
blend providing as little as 1.5% ALA is superior to the
plant oil blend for increasing brain DHA, even when the
recommended DHA and AA levels are exogenously pro-
vided, suggesting that the endogenous synthesis of n-3
LC-PUFA synthesis can be enhanced [35]. Formula fed
infants could then benefit from the supplementation of
formula with dairy lipids and plant oils by attaining
higher erythrocyte membrane omega-3 FA content than
infants receiving a formula supplemented with plant oils
or plants oils enriched with LC-PUFA. The achievement
of optimal DHA levels in formula fed infants could also
be associated with improved neurocognitive and visual
functions, as previously underlined by other studies [25-
27]. Not only the erythrocyte membrane omega-3 FA
levels will be investigated but also the other erythrocyte
membrane FA levels, the plasma lipid profile, the insulin
growth factor 1, the formula tolerance, the growth and
body composition. Gaining insight in the effects of the
supplementation of a formula with dairy lipids and plant
oils in healthy full-term infants could improve the fat
content, composition and structure of infant formulas,
making them closer to human milk.Abbreviations
AE: Adverse event; ALA: Alpha linolenic acid; AA: Arachidonic acid;
DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; EFA: Essential
fatty acid; EPA: Eicosapentaenoic acid; FA: Fatty acid; IGF1: Insulin-like growth
factor 1; LA: Linoleic acid; LC-PUFA: Long chain polyunsaturated fatty acid;
SAE: Serious adverse event.Competing interests
Lactalis Nutrition Santé, Torcé, France for the financial support and for
providing the study formulas.Authors’ contributions
Paola Roggero, Pascale Le Ruyet and Fabio Mosca formulated the research
question and wrote the study protocol. Daniela Morniroli, Amandine Ligneul
contributed to the development of the protocol. Francesca Garbarino gave
advice on statistical analysis. Charlotte Baudry, Maria Lorella Giannì, Paola
Roggero wrote the draft of the manuscript and the other authors reviewed
the manuscript. All authors approved the final version of the manuscript.
Author details
1Neonatal Intensive Care Unit (NICU), Department of Clinical Science and
Comunity Health, Fondazione IRCCS “Ca’ Granda” Ospedale Maggiore
Policlinico, University of Milan, Milan, Italy. 2Lactalis Recherche et
Développement, 8 Fromy - CS 60082, 35240, Retiers, France.
Received: 10 August 2012 Accepted: 11 October 2012
Published: 17 October 2012References
1. Michaelsen KF, Weaver L, Branca F, Robertson A: Feeding and nutrition of
infants and young children. European Series N° 87th edition. Copenhagen:
WHO Regional Publications; 2000.
2. American Academy of Pediatrics Section on Breastfeeding: Breastfeeding
and the use of human milk. Pediatrics 2005, 115:496–506.
3. ESPGHAN Committee on Nutrition, Agostoni C, Braegger C, Decsi T, Kolacek
S, Koletzko B, Michaelsen KF, Mihatsch W, Moreno LA, Puntis J, Shamir R,
Szajewska H, Turck D, van Goudoever J: Breast-feeding: A commentary by
the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2009,
49:112–125.
4. Jensen RG, Hagerty MM, McMahon KE: Lipids of human milk and infant
formulas: a review. Am J Clin Nutr 1978, 31:990–1016.
5. Innis SM: Dietary (n-3) fatty acids and brain development. J Nutr 2007,
137:855–859.
6. Percy P, Percy A, Vilbersson G, Mansson JE: Polyunsaturated fatty acid
accretion in first- and second-trimester human fetal brain: lack of
correlation with levels in paired placental samples. Biochem Mol Med
1996, 59:38–43.
7. Clandinin MT, Chapell JE, Leong S, Heim T, Swyer PR, Chance PW:
Intrauterine fatty acid accretion rates in human brain: implications for
fatty acid requirements. Early Hum Dev 1980, 4:121–129.
8. Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR, Chance GW:
Extrauterine fatty acid accretion in infant brain: implications for fatty
acid requirements. Early Hum Dev 1980, 4:131–138.
9. Martinez M, Mougan I: Fatty acid composition of human brain
phospholipids during normal development. J Neurochem 1998,
71:2528–2533.
10. Martinez M: Tissue levels of polyunsaturated fatty acids during early
human development. J Pediatr 1992, 120(Suppl 4):129–138.
11. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF: The essentiality of
long chain n-3 fatty acids in relation to development and function of
the brain and retina. Prog Lipid Res 2001, 40:1–94.
12. Diau GY, Hsieh A, Sarkadi-Nagy E, Wijendran V, Nathanielsz P, Brenna JT: The
influence of long chain polyunsaturate supplementation on
docosahexaenoic acid and arachidonic acid in baboon neonate central
nervous system. BMC Med 2005, 3:11.
13. McCann JC, Ames BN: Is docosahexaenoic acid, a n-3 long-chain
polyunsaturated fatty acid, required for development of normal brain
function? An overview of evidence from cognitive and behavioral tests
in humans and animals. Am J Clin Nutr 2005, 82:281–295.
14. Arterburn LM, Hall EB, Oken H: Distribution, interconversion, and dose
response of n-3 fatty acids in humans. Am J Clin Nutr 2006,
83(Suppl 6):1467–1476.
15. Hadders-Algra M: Effect of long-chain polyunsaturated fatty acid
supplementation on neurodevelopmental outcome in full-term infants.
Nutrients 2010, 2:790–804.
16. De Lucchi C, Pita ML, Faus MJ, Periago JL, Gil A: Changes in the fatty acid
composition of plasma and red blood cell membrane during the first
hours of life in human neonates. Early Hum Dev 1987, 15:85–93.
17. Larque E, Demmelmair H, Koletzko B: Perinatal supply and metabolism
of long-chain polyunsaturated fatty acids: importance for the early
development of the nervous system. Ann N Y Acad Sci 2002,
967:299–310.
18. Babin F, Limasset B, Descomps B, Rieu D, de Paulet FM, de Paulet AC:
Nervonic acid in red blood cell sphingomyelin in premature infants: an
index of myelin maturation. Lipids 1993, 28:627–630.
19. Fekete K, Marosvölgyi T, Jakobik V, Decsi T: Methods of assessment of n-3
long-chain polyunsaturated fatty acid status in humans: a systematic
review. Am J Clin Nutr 2009, 89:2070S–2084S.
20. Lucas A, Morley R, Cole TJ, Lister G, Leeson-Payne C: Breast milk and
subsequent intelligence quotient in children born preterm. Lancet 1992,
339:261–264.
21. Anderson JW, Johnstone BM, Remley DT: Breast-feeding and cognitive
development: a meta-analysis. Am J Clin Nutr 1999, 70:525–535.
22. Makrides M, Simmer K, Goggin M, Gibson RA: Erythrocyte
docosahexaenoic acid correlates with the visual response of healthy,
term infants. Pediatr Res 1993, 33:425–427.
23. Farquharson J, Jamieson EC, Abbasi KA, Patrick WJ, Logan RW, Cockburn F:
Effect of diet on the fatty acid composition of the major phospholipids
of infant cerebral cortex. Arch Dis Child 1995, 72:198–203.
Giannì et al. BMC Pediatrics 2012, 12:164 Page 7 of 7
http://www.biomedcentral.com/1471-2431/12/16424. Miller MR, Seifert J, Szabo NJ, Clare-Salzler M, Rewers M, Norris JM:
Erythrocyte membrane fatty acid content in infants consuming formulas
supplemented with docosahexaenoic acid (DHA) and arachidonic acid
(ARA): an observational study. Matern Child Nutr 2010, 6:338–346.
25. Koletzko B, Lien E, Agostoni C, Böhles H, Campoy C, Cetin I, Decsi T,
Dudenhausen JW, Dupont C, Forsyth S, Hoesli I, Holzgreve W, Lapillonne A,
Putet G, Secher NJ, Symonds M, Szajewska H, Willatts P: Uauy R; World
Association of Perinatal Medicine Dietary Guidelines Working Group: The
roles of long-chain polyunsaturated fatty acids in pregnancy, lactation
and infancy: review of current knowledge and consensus
recommendations. J Perinat Med 2008, 36:5–14.
26. SanGiovanni JP, Berkey CS, Dwyer JT, Colditz G: Dietary essential fatty
acids, long-chain polyunsaturated fatty acids, and visual resolution
acuity in healthy full-term infants: a systematic review. Early Hum Dev
2000, 57:165–188.
27. Campoy C, Escolano-Margarit MV, Anjos T, Szajewska H, Uauy R: Omega 3
fatty acids on child growth, visual acuity and neurodevelopment.
Br J Nutr 2012, 107(Suppl 2):85–106.
28. Courville AB, Harel O, Lammi-Keefe CJ: Consumption of a DHA-containing
functional food during pregnancy is associated with lower infant
ponderal index and cord plasma insulin concentration. Br J Nutr 2011,
27:1–5.
29. Koletzko B, Bremer HJ: Fat content and fatty acid composition of infant
formulas. Acta Paediatr Scand 1989, 78:513–521.
30. Michalski MC, Ollivon M, Briard V, Leconte N, Lopez C: Native fat globules
of different sizes selected from raw milk: thermal and structural
behavior. Chem Phys Lipids 2004, 132:247–261.
31. Berger A, Fleith M, Crozier G: Nutritional implications of replacing bovine
milk fat with vegetable oil in infant formulas. J Pediatr Gastroenterol Nutr
2000, 30:115–130.
32. Jensen RG, Ferris AM, Lammi-Keefe CJ: Lipids in human milk and infant
formulas. Annu Rev Nutr 1992, 12:417–441.
33. Jensen RG, Ferris AM, Lammi-Keefe CJ: The composition of milk fat.
J Dairy Sci 1991, 74:3228–3243.
34. Dabadie H, Peuchant E, Bernard M, LeRuyet P, Mendy F: Moderate intake
of myristic acid in sn-2 position has beneficial lipidic effects and
enhances DHA of cholesteryl esters in an interventional study.
J Nutr Biochem 2005, 16:375–382.
35. Du Q, Martin JC, Agnani G, Pages N, Leruyet P, Carayon P, Delplanque B:
Dairy fat blends high in α-linolenic acid are superior to n-3 fatty-acid-
enriched palm oil blends for increasing DHA levels in the brains of
young rats. J Nutr Biochem 2012,: . Epub ahead of print.
36. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A: Clinical validation
and guidelines for the SCORAD index: consensus report of the European
Task Force on Atopic Dermatitis. Dermatology 1997, 195:10–19.
37. World Health Organization Multicentre Growth Reference Study Group.WHO
Child Growth Standards: length/height-for age, weight-for-age, weight for-
length, weight-for-height and body mass index for-age: methods and
development; 2006. Available: http://www.euro-growth.org/.
38. Ma GS, Yao M, Liu Y, Lin A, Zou H, Urlando A, Wong WW, Nommsen-Rivers
L, Dewey KG: Validation of a new pediatric air displacement
plethysmograph for assessing body composition in infants. Am J Clin
Nutr 2004, 79:653–660.
39. Roggero P, Giannì ML, Amato O, Piemontese P, Morniroli D, Wong WW,
Mosca F: Evaluation of air-displacement plethysmography for body
composition assessment in preterm infants. Pediatr Res 2012, 72:316–320.
doi:10.1186/1471-2431-12-164
Cite this article as: Giannì et al.: The influence of a formula
supplemented with dairy lipids and plant oils on the erythrocyte
membrane omega-3 fatty acid profile in healthy full-term infants: a
double-blind randomized controlled trial. BMC Pediatrics 2012 12:164.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
